Literature DB >> 32208559

Eli Lilly and Company Insulins - A Century of Innovation.

J K Malone1, J H Jr Anderson2, H A Wolpert3, L L Ilag3, B H Frank4, M R De Felippis5, C D Paavola6, A L Orr1, J M Beals7.   

Abstract

Eli Lilly and Company has played a pivotal role in the development of insulin products since its discovery in 1921. Through their dedication to pharmaceutical innovation, Josiah K. Lilly Sr. and George HA Clowes, in close collaborations with the University of Toronto, made insulin commercially available in 1923. Other innovations include the development and commercialization of the first biosynthetic human insulin, a rapid-acting insulin analog and analog mixtures. Lilly has advanced the field of knowledge with significant efforts toward developing a hepatic preferential basal insulin. Other important insulin projects include the first concentrated rapid-acting insulin analog, clinical studies supporting the use of highly concentrated human insulin, and an advanced clinical development program for an ultra-rapid insulin analog. Lilly's commitment to people affected with diabetes remains strong and will continue into the future through collaborative research, innovative product development and investing in advanced technologies. Copyright© of YS Medical Media ltd.

Entities:  

Keywords:  Basaglar; Humalog; Humulin; Iletin; Insulin; Lispro; U-500; Ultra-rapid

Mesh:

Substances:

Year:  2020        PMID: 32208559     DOI: 10.17458/per.vol17.2020.jjh.elilillycompanyinsulin

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  2 in total

1.  Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain.

Authors:  Miriam Rubio de Santos; Esther Artime; Natalia Duque; Silvia Díaz-Cerezo; Erik Spaepen; Ágata Carreño; Alberto Fernández
Journal:  Diabetes Ther       Date:  2022-04-21       Impact factor: 3.595

Review 2.  The discovery of insulin revisited: lessons for the modern era.

Authors:  Gary F Lewis; Patricia L Brubaker
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.